Sam Brusco, Associate Editor08.03.23
STERIS has completed its previously announced $540 million purchase of the surgical instrumentation, laparoscopic instrumentation, and sterilization control assets from BD.
The acquisition deal was first announced in June.
“We are pleased to announce the closing of this acquisition, as the brands we are adding will strengthen, complement and expand STERIS’s product offerings within our Healthcare segment,” Dan Carestio, president and CEO of STERIS told the press. “We welcome these teams to STERIS and look forward to working together to enhance our value to our customers.”
This divestiture includes BD’s V. Mueller, Snowden-Pencer, and Genesis branded products and three manufacturing facilities located in St. Louis, Cleveland, and Tuttlingen, Germany. About 360 employees supporting the platform have transferred to STERIS as well.
Divesting the platform, according to BD, progresses the “Simplify” pillar of its BD 2025 strategy and is a critical step in simplifying its product portfolio and manufacturing network.
STERIS provides products and services that support infection prevention. The company has $5 billion in global sales with over 17,000 associates. The company serves the healthcare, pharmaceutical, medical device, and dental segments.
BD’s surgical instrumentation platform complements STERIS’ Healthcare segment and will help the company better serve hospital and surgery centers.
The acquisition deal was first announced in June.
“We are pleased to announce the closing of this acquisition, as the brands we are adding will strengthen, complement and expand STERIS’s product offerings within our Healthcare segment,” Dan Carestio, president and CEO of STERIS told the press. “We welcome these teams to STERIS and look forward to working together to enhance our value to our customers.”
This divestiture includes BD’s V. Mueller, Snowden-Pencer, and Genesis branded products and three manufacturing facilities located in St. Louis, Cleveland, and Tuttlingen, Germany. About 360 employees supporting the platform have transferred to STERIS as well.
Divesting the platform, according to BD, progresses the “Simplify” pillar of its BD 2025 strategy and is a critical step in simplifying its product portfolio and manufacturing network.
STERIS provides products and services that support infection prevention. The company has $5 billion in global sales with over 17,000 associates. The company serves the healthcare, pharmaceutical, medical device, and dental segments.
BD’s surgical instrumentation platform complements STERIS’ Healthcare segment and will help the company better serve hospital and surgery centers.